AACR Project GENIE
AACR Project GENIE is real-world tumour sequencing data shared by leading cancer centres.
Biopharma Collaborative adds detailed outcomes for NSCLC, CRC, breast, prostate, pancreatic, bladder.
Pages like this
not linked directly; found by shared links- CollectioncBioPortal for Cancer Genomics
Shares A global rapid tissue donation network for metastatic disease, Let patients themselves donate their records and samples for ultra-rare cancers, An organotropism atlas that predicts where a cancer will spread, Every tumour genomic report machine-readable and deposited nationally.
- CollectionSEER (Surveillance, Epidemiology, and End Results)
Shares Emulate the trial in real-world data first to decide which trials to run, Link every national cancer registry to tumour genomics, An organotropism atlas that predicts where a cancer will spread, Randomise inside the registry that already follows every patient.
- CollectionOncoKB
Shares Every tumour genomic report machine-readable and deposited nationally, Pool every immunotherapy trial's biomarker data into one commons, Check whether a tumour can still show itself to the immune system.
- IdeaUniversal tumour and germline sequencing at diagnosis feeding a shared learning system
Shares American Association for Cancer Research (AACR), Real-world evidence, Data silos.
- TermNext-generation sequencing (NGS)
Shares Link every national cancer registry to tumour genomics, Every tumour genomic report machine-readable and deposited nationally, Data silos.
- IdeaTreat resistance like an infectious disease and run national surveillance
Shares Real-world evidence, Data silos, Acquired resistance to every therapy.
- CompanyFoundation Medicine (Roche)
Shares Emulate combination trials from real-world data to triage which ones to run, Every tumour genomic report machine-readable and deposited nationally, Data silos.
- PersonCharles Swanton
Shares A global rapid tissue donation network for metastatic disease, Check whether a tumour can still show itself to the immune system.
